NXGL Quote, Financials, Valuation and Earnings

The Cooper Companies has a net margin of -25.37% compared to NexGel's net margin of 8.75%. NexGel's return on equity of -59.55% beat The Cooper Companies's return on equity of 5.15%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 151.05%. On the other hand The Cooper Companies has an analysts' consensus of $92.09 which suggests that it could grow by 25.7%. Given that NexGel has higher upside potential than The Cooper Companies, analysts believe NexGel is more attractive than The Cooper Companies.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Cooper Companies has a beta of 0.985, suggesting its less volatile than the S&P 500 by 1.451%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. NexGel pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are smaller than The Cooper Companies quarterly revenues of $1B. NexGel's net income of -$712K is lower than The Cooper Companies's net income of $87.7M. Notably, NexGel's price-to-earnings ratio is -- while The Cooper Companies's PE ratio is 35.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.62x versus 3.69x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

OrthoPediatrics has a net margin of -25.37% compared to NexGel's net margin of -20.34%. NexGel's return on equity of -59.55% beat OrthoPediatrics's return on equity of -11.21%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 151.05%. On the other hand OrthoPediatrics has an analysts' consensus of $36.71 which suggests that it could grow by 62.09%. Given that NexGel has higher upside potential than OrthoPediatrics, analysts believe NexGel is more attractive than OrthoPediatrics.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.802%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are smaller than OrthoPediatrics quarterly revenues of $52.4M. NexGel's net income of -$712K is higher than OrthoPediatrics's net income of -$10.7M. Notably, NexGel's price-to-earnings ratio is -- while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.62x versus 2.47x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -25.37% compared to NexGel's net margin of -391.35%. NexGel's return on equity of -59.55% beat Innovative Eyewear's return on equity of -97.69%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 151.05%. On the other hand Innovative Eyewear has an analysts' consensus of $7.00 which suggests that it could grow by 228.64%. Given that Innovative Eyewear has higher upside potential than NexGel, analysts believe Innovative Eyewear is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are larger than Innovative Eyewear quarterly revenues of $454.5K. NexGel's net income of -$712K is higher than Innovative Eyewear's net income of -$1.8M. Notably, NexGel's price-to-earnings ratio is -- while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.62x versus 2.40x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -25.37% compared to NexGel's net margin of -127.29%. NexGel's return on equity of -59.55% beat Staar Surgical's return on equity of -17.97%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 151.05%. On the other hand Staar Surgical has an analysts' consensus of $19.20 which suggests that it could grow by 12.35%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.753%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are smaller than Staar Surgical quarterly revenues of $42.6M. NexGel's net income of -$712K is higher than Staar Surgical's net income of -$54.2M. Notably, NexGel's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.62x versus 3.03x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.